<DOC>
	<DOCNO>NCT00282360</DOCNO>
	<brief_summary>Patients coronary artery disease abnormal cardiac metabolism . The hypothesis study shift cardiac metabolism free fatty acid glucose improve myocardial ischemia</brief_summary>
	<brief_title>Effect Metabolic Therapy Patients With Chronic Ischemic Heart Disease</brief_title>
	<detailed_description>The present study evaluate effect free fatty acid inhibition Trimetazidine silent myocardial ischemia total ischemic burden coronary artery disease patient type II diabetes . Patients undergo ambulatory ECG monitoring baseline randomize receive top thei standard anti-anginal therapy trimetazidine placebo 6 month . Patients repeat ambulatory ECG monitoring end study</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Trimetazidine</mesh_term>
	<criteria>coronary artery disease type II diabetes mellitus unstable coronary artery syndromes impaired liver kidney function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>diabetes mellitus</keyword>
</DOC>